Literature DB >> 28109634

The American College of Radiology and the American Brachytherapy Society practice parameter for the performance of radionuclide-based high-dose-rate brachytherapy.

Beth A Erickson1, Nathan H J Bittner2, Manjeet Chadha3, Firas Mourtada4, D Jeffrey Demanes5.   

Abstract

Brachytherapy is a radiation therapy method in which radionuclide sources are used to deliver a radiation dose at a distance of up to a few centimeters by surface, intracavitary, intraluminal, or interstitial application. This practice parameter refers only to the use of radionuclides for brachytherapy. Brachytherapy alone or combined with external beam therapy plays an important role in the management and treatment of patients with cancer. High-dose-rate (HDR) brachytherapy uses radionuclides such as iridium-192 at dose rates of 20 cGy per minute (12 Gy per hour) or more to a designated target point or volume. High-dose-rate (HDR) brachytherapy is indicated for treating malignant or benign tumors where the treatment volume or targeted points are defined and accessible.
Copyright © 2016 American Brachytherapy Society and American College of Radiology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HDR brachytherapy; High-dose-rate brachytherapy; Oncologic practice; Radiation oncologist; Radiation therapy; Radioactive sources; Radionuclides

Mesh:

Substances:

Year:  2017        PMID: 28109634     DOI: 10.1016/j.brachy.2016.05.006

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  3 in total

Review 1.  Current status of brachytherapy in cancer treatment - short overview.

Authors:  Janusz Skowronek
Journal:  J Contemp Brachytherapy       Date:  2017-12-30

2.  COMP report: CPQR technical quality control guidelines for brachytherapy remote afterloaders.

Authors:  Normand Frenière
Journal:  J Appl Clin Med Phys       Date:  2018-02-07       Impact factor: 2.102

3.  Comparison of the IPSA and HIPO algorithms for interstitial tongue high-dose-rate brachytherapy.

Authors:  Chang Heon Choi; So-Yeon Park; Jong Min Park; Hong-Gyun Wu; Jin-Ho Kim; Jung-In Kim
Journal:  PLoS One       Date:  2018-10-04       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.